James Momtazee Net Worth

The estimated Net Worth of James C Momtazee is at least $3.76 Milion dollars as of 29 December 2021. Mr. Momtazee owns over 80,000 units of BridgeBio Pharma Inc stock worth over $2,476,863 and over the last 21 years he sold BBIO stock worth over $87,590. In addition, he makes $1,199,990 as Independent Director at BridgeBio Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Momtazee BBIO stock SEC Form 4 insiders trading

James has made over 3 trades of the BridgeBio Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 80,000 units of BBIO stock worth $1,160,000 on 29 December 2021.

The largest trade he's ever made was buying 80,000 units of BridgeBio Pharma Inc stock on 29 December 2021 worth over $1,160,000. On average, James trades about 2,525 units every 87 days since 2003. As of 29 December 2021 he still owns at least 88,491 units of BridgeBio Pharma Inc stock.

You can see the complete history of Mr. Momtazee stock trades at the bottom of the page.

James Momtazee biography

James C. Momtazee serves as Independent Director of the Company. He is a Member of KKR, and he has been employed by Kohlberg Kravis Roberts & Co. L.P., a private equity and alternative asset management firm, since 1996. Mr. Momtazee currently serves on the board of directors of PRA Health Sciences, Inc. (Nasdaq: PRAH), a global contract research organization as well as several private companies. He previously served on the boards of directors of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a biopharmaceutical company, from 2004 to 2014, HCA Healthcare Inc. (formerly HCA Holdings Inc.; NYSE: HCA), a health care services company, from 2006 to 2014, and Entellus Medical, Inc., a medical technology company, from 2017 to 2018. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

What is the salary of James Momtazee?

As the Independent Director of BridgeBio Pharma Inc, the total compensation of James Momtazee at BridgeBio Pharma Inc is $1,199,990. There are 9 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.

How old is James Momtazee?

James Momtazee is 48, he's been the Independent Director of BridgeBio Pharma Inc since 2016. There are 13 older and 9 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.

What's James Momtazee's mailing address?

James's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.

Insiders trading at BridgeBio Pharma Inc

Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo oraz Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.

What does BridgeBio Pharma Inc do?

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.

Complete history of Mr. Momtazee stock trades at Jazz Pharmaceuticals plc, PRA Health Sciences Inc, Global X Funds oraz BridgeBio Pharma Inc

BridgeBio Pharma Inc executives and stock owners

BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:

• Neil Kumar,
  Chief Executive Officer, Director
• Charles Homcy,
  Chairman of Pharmaceuticals, Lead Director
• Uma Sinha,
  Chief Scientific Officer
• Brian Stephenson,
  Chief Financial Officer
• Eric Aguiar,
  Independent Director
• Ali Satvat,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Neil Kumar Ph.D.,
  Co-Founder, CEO & Director
• Dr. Brian C. Stephenson C.F.A., Ph.D.,
  CFO, Sec. & Principal Accounting Officer
• James Momtazee,
  Independent Director
• Richard Scheller,
  Chairman of Research and Development, Director
• Dr. Michael Thomas Henderson M.D.,
  Chief Bus. Officer
• Dr. Charles J. Homcy M.D.,
  Chairman of Pharmaceuticals & Lead Director
• Dr. Richard H. Scheller Ph.D.,
  Chairman of R&D and Director
• Dr. Cameron Turtle DPHIL, Ph.D.,
  Chief Strategy Officer
• Randal Scott,
  Independent Director
• Brenton Saunders,
  Independent Director
• Andrew Lo,
  Independent Director
• Ronald Daniels,
  Independent Director
• Michael Henderson,
  Chief Business Officer
• Cameron Turtle,
  Senior Vice President - Portfolio Management and Corporate Development
• Frank Mccormick,
  Chairman of Oncology
• Dr. Frank McCormick Ph.D.,
  Chairman of Oncology
• Grace Rauh,
  VP of Communications
• Dr. Uma Sinha Ph.D.,
  Chief Scientific Officer
• Yi Ching Yau,
  Chief Accounting Officer
• Genetic Disorder L.P.Kkr Ge...,
  
• Management Holdings L.P.Kkr...,
  
• Douglas A. Dachille,
  
• Fred Hassan,
  
• Global Performance Llc Viki...,
  
• Global Investors Lp Viking ...,
  
• Genetic Disorder L.P.Robert...,
  
• Yi Ching Yau,
  Chief Accounting Officer
• Brian M. Stolz,
  Chief Operating Officer
• Hannah Valantine,
  
• Brent L Saunders,
  Director
• Andrea Ellis,
  
• Global Investors Lp Viking ...,
  
• Thomas Trimarchi,
  President and COO